Boyd Peter E. 4
4 · Aquestive Therapeutics, Inc. · Filed Apr 13, 2026
Research Summary
AI-generated summary of this filing
Aquestive (AQST) Chief People Officer Peter Boyd Receives Award
What Happened
Peter E. Boyd, Chief People Officer of Aquestive Therapeutics (AQST), received a grant of 60,000 performance stock units (PSUs) on March 7, 2025. The Form 4 reports the award as a derivative acquisition at $0.00 per unit (transaction code A). This was an equity award, not a cash purchase or sale, and does not represent immediate ownership of common shares until vesting conditions are met.
Key Details
- Transaction date: 2025-03-07; Form 4 filed: 2026-04-13 (late filing; footnote F1 cites an inadvertent administrative oversight).
- Grant: 60,000 PSUs (derivative award) at $0.00 per unit; reported acquisition value $0.
- Shares owned after transaction: not disclosed in the filing.
- Footnote F2 (PSU terms): each PSU is a contingent right to one common share; performance measured from March 7, 2025 through March 7, 2028; if earned, 100% vests on March 7, 2028. "Performance Price" uses 30-day average Nasdaq prices over defined measurement periods (see filing).
- Transaction code: A = Award/Grant; timeliness indicator: L (late).
Context
PSUs are contingent awards that vest only if performance conditions are met over the specified multi-year period; they do not represent immediately tradable shares. Awards are common as part of executive compensation and are different from open-market purchases (which can signal personal conviction). The late filing is an administrative matter noted in the Form 4; it does not change the nature of the grant but delays public disclosure.
Insider Transaction Report
- Award
Performance Stock Units
[F1][F2]2025-03-07+60,000→ 60,000 totalExp: 2028-03-07→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]This Form 4 was filed late due to an inadvertent administrative oversight.
- [F2]Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).